Who are BACTROBAN® Nasal ong's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mupirocin + Chlorhexidin, Mupirocin Ointment [Treatment], Chlorhexidine, Mupirocin, Intranasal Mupirocin and Topical Chlorhexidine, mupirocin 2% ointment, clindamycin 1% / benzoyl peroxide 5% tube.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bactroban-nasal-ong.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

BACTROBAN® Nasal ong — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BACTROBAN® Nasal ong (BACTROBAN® Nasal ong) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antibiotic. Area: Infectious Disease.

marketed Topical antibiotic Isoleucyl-tRNA synthetase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

BACTROBAN® Nasal ong (BACTROBAN® Nasal ong) — Lindenhofgruppe AG. Mupirocin is a topical antibiotic that inhibits bacterial protein synthesis by binding to isoleucyl-tRNA synthetase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BACTROBAN® Nasal ong TARGET	BACTROBAN® Nasal ong	Lindenhofgruppe AG	marketed	Topical antibiotic	Isoleucyl-tRNA synthetase
Mupirocin + Chlorhexidin	Mupirocin + Chlorhexidin	B. Braun Medical SA	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane (chlorhexidine)
Mupirocin Ointment [Treatment]	Mupirocin Ointment [Treatment]	US Department of Veterans Affairs	marketed	Topical antibiotic	Isoleucyl-tRNA synthetase
Chlorhexidine, Mupirocin	Chlorhexidine, Mupirocin	University of Tennessee	marketed	Topical antimicrobial combination	Bacterial cell membrane (chlorhexidine); isoleucyl-tRNA synthetase (mupirocin)
Intranasal Mupirocin and Topical Chlorhexidine	Intranasal Mupirocin and Topical Chlorhexidine	University of Maryland, Baltimore	marketed	Topical antibiotic combination	Bacterial isoleucyl-tRNA synthetase (mupirocin); bacterial cell membrane and proteins (chlorhexidine)
mupirocin 2% ointment	mupirocin 2% ointment	Philippine Dermatological Society	phase 3	bacterial protein synthesis inhibitor	isoleucyl-tRNA synthetase
clindamycin 1% / benzoyl peroxide 5% tube	clindamycin 1% / benzoyl peroxide 5% tube	Sanofi	marketed	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antibiotic class)

Lindenhofgruppe AG · 1 drug in this class
US Department of Veterans Affairs · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BACTROBAN® Nasal ong — Competitive Intelligence Brief. https://druglandscape.com/ci/bactroban-nasal-ong. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab